Inhaled budesonide safe for infants with asthma

	Tweet

Budesonide inhalation suspension (BIS) is a safe asthma treatment for infants, according to a new study.

Although previous trials have shown that BIS can be safely used to treat children, only a few infants less than a year old were included in these studies. As such, the US Food and Drug Administration requested additional data showing that budesonide inhalation is safe for this group.

The current study, reported in the Journal of Pediatrics, involved 141 infants 6 to 12 months of age with mild-to-moderate persistent asthma or recurrent wheeze. The infants were randomly assigned to treatment with one of two doses of BIS or and inactive placebo once daily for 12 weeks.

Overall, no significant differences were seen between the groups in the type or frequency of adverse events, lead author Dr. William E. Berger, from Allergy and Asthma Associates of Southern California in Mission Viejo, and colleagues note.

The results indicate that BIS is a safe and well-tolerated treatment for asthma and wheeze in infants, the investigators conclude.

The study was supported by AstraZeneca LP, which markets BIS as Pulmicort Respules.

SOURCE: Journal of Pediatrics, January 2005.

RELATED STORIES:
Acetaminophen could up asthma, wheezing risk   Cleaning Products Link To Asthma   Water-damaged buildings tied to workers’ asthma   Pregnant women with asthma symptoms face risks   Mental distress linked with asthma flares   Children with asthma have more emotional problems   Cigarette Use May Explain Asthma Epidemic in Children   Half of ‘untreatable’ asthma cases may be treatable   Scottish smoking ban cuts childhood asthma attacks   Increased smoking may be linked to asthma epidemic   Discovery could lead to new therapies for asthma, COPD   Road traffic tied to poverty-stricken kids’ asthma

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]